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Loss of the endothelial glycocalyx is
associated with increased E-selectin
mediated adhesion of lung tumour cells to
the brain microvascular endothelium
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Abstract
Background: Arrest of metastasising lung cancer cells to the brain microvasculature maybe mediated by interactions
between ligands on circulating tumour cells and endothelial E-selectin adhesion molecules; a process likely to be
regulated by the endothelial glycocalyx. Using human cerebral microvascular endothelial cells and non-small cell lung
cancer (NSCLC) cell lines, we describe how factors secreted by NSCLC cells i.e. cystatin C, cathepsin L, insulin-like growth
factor-binding protein 7 (IGFBP7), vascular endothelial growth factor (VEGF) and tumour necrosis factor-alpha (TNF-α),
damage the glycocalyx and enhance initial contacts between lung tumour and cerebral endothelial cells.
Methods: Endothelial cells were treated with tumour secreted-proteins or lung tumour conditioned medium (CM).
Surface levels of E-selectin were quantified by ELISA. Adhesion of A549 and SK-MES-1 cells was examined under flow
conditions (1 dyne/cm2). Alterations in the endothelial glycocalyx were quantified by binding of fluorescein
isothiocyanate-linked wheat germ agglutinin (WGA-FITC).
Results: A549 and SK-MES-1 CM and secreted-proteins significantly enhanced endothelial surface E-selectin levels
after 30 min and 4 h and tumour cell adhesion after 30 min, 4 and 24 h. Both coincided with significant
glycocalyx degradation; A549 and SK-MES-1 CM removing 55 ± 12 % and 58 ± 18.7 % of WGA-FITC binding,
respectively. Inhibition of E-selectin binding by monoclonal anti-E-selectin antibody completely attenuated tumour
cell adhesion.
Conclusion: These data suggest that metastasising lung cancer cells facilitate their own adhesion to the brain
endothelium by secreting factors that damage the endothelial glycocalyx, resulting in exposure of the previously shielded
adhesion molecules and engagement of the E-selectin-mediated adhesion axis.
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Introduction
Brain metastases arising from primary lung cancer contrib-
ute significantly to the morbidity and mortality of the dis-
ease. These tumours present a challenging clinical scenario
since they are generally resistant to conventional chemo-
therapy due to the inability of these drugs to cross the
blood–brain barrier (BBB) [1]. Insights into the molecular
mechanisms of the metastatic process will aid development
of more effective therapeutic strategies.
In order to form metastases, tumour cells must success-
fully complete a sequence of key, inter-related steps initi-
ated by extensive proliferation of the primary tumour cells
and their invasion of the surrounding extracellular matrix
(ECM). These malignant cells then dissociate from the pri-
mary site, intravasate the circulation and form tumour
microemboli, which eventually arrest along the microvascu-
lature of a target organ. Tumour cells attach to the endo-
thelium, extravasate and ultimately colonize to form
secondary metastatic lesions. Although, the exact
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mechanisms of tumour cell adhesion in the vasculature of
specific organs remain unknown, parallels have been
drawn with the leukocyte-endothelial cell (EC) interactions
that occur during inflammation. Here, initial leukocyte
‘tethering’ and ‘rolling’ is primarily mediated by endothelial
surface proteins from the selectin family (E- and P- selec-
tin) whereas stronger bonds resulting in leukocyte arrest,
firm adhesion and finally transmigration are determined by
members of the endothelial immunoglobulin superfamily
[intercellular adhesion molecule-1 (ICAM-1) and vascular
cell adhesion molecule-1 (VCAM-1)]. These same adhe-
sion molecules may be involved in metastatic tumour cell
adhesion [2, 3]. Several studies [4, 5] have shown that al-
tered E-selectin expression on activated endothelial cells
greatly influences metastasis formation and subsequent
colonization, and increased circulating E-selectin levels
have been associated with metastasis of both breast and
colon carcinoma cells to the liver [6, 7]. Data on the role of
endothelial adhesion molecules in lung tumour metastasis
to the brain are very limited; however Soto et al. did re-
cently report a role for VCAM-1 and activated leukocyte
cell adhesion molecule (ALCAM) in the early stages of
brain metastasis in a mouse model [8].
It is now becoming recognised that a major physiological
regulator of adhesion of circulating cells to the endothelium
is the endothelial surface layer (glycocalyx); a dense intra-
luminal layer of transmembrane and membrane-bound
molecules [9]. It is physically linked to the endothelium
through key ‘backbone’ proteoglycans and glycoproteins,
which together form a mesh into which both endothelium-
and plasma-derived soluble molecules are incorporated
[10]. The glycocalyx is a dynamic structure maintained by a
tightly controlled equilibrium between degradation and
synthesis of the principal components.
If lung tumour cells utilise the cerebral endothelial adhe-
sion molecules to initially adhere to the brain microvascula-
ture during metastasis, then the glycocalyx may play a
critical role in this process by sterically influencing the
ligand-receptor binding dynamics. In health, the EC adhe-
sion molecules are embedded within the glycocalyx layer
since glycocalyx thickness has been reported up to 1 μm;
considerably larger than the 10 nm span of EC adhesion
molecules and receptors [11]. Thus, endothelial adhesion
molecules are exposed by loss of the glycocalyx. This raises
the intriguing possibility that circulating lung tumour
microemboli arrested in the cerebral microcirculation have
a metastatic potential that enables them to secrete factors
that locally degrade the glycocalyx; enhancing endothelial
adhesion molecule exposure and facilitating their own
adhesion and ultimately transmigration. Thus the objective
of this study was to identify key pro-metastatic factors
secreted by lung tumour cells and to investigate the effect
of these factors on cerebral EC adhesion molecule expos-
ure, glycocalyx integrity and binding of lung tumour cells.
Here, we report for the first time that human non-small
cell lung cancer (NSCLC) cells (A549; adenocarcinoma and
SK-MES-1; squamous cell carcinoma) secrete factors that
enhance human cerebral endothelial adhesion molecule
exposure and increase adhesion of tumour cells to the cere-
bral endothelium. Importantly, we identify E-selectin as the
key adhesion molecule involved in the initial tethering of
the lung tumour cells and for the first time demonstrate
that loss of integrity of the cerebral endothelial glycocalyx
enhances exposure of E-selectin and tumour cell adhesion.
Our results highlight a potentially important mechanism by
which malignant lung tumour cells can enhance their own
metastatic potential; raising the possibility that interven-
tions designed to maintain glycocalyx integrity may have
important clinical benefit in reducing brain metastases in
primary lung tumour patients.
Materials and methods
Cell culture and preparation of tumour
conditioned-medium
A transformed human cerebral microvascular endothe-
lial cell line, hCMEC/D3, was kindly provided by Dr.
Pierre-Olivier Couraud, Institut Cochin, INSERM U1016,
France. This cell line has been fully characterized by Dr
Couraud and shown to express a range of endothelial and
BBB-specific markers [12]. Cells were cultured and grown
to confluence in rat tail collagen type I coated tissue
culture flasks at 37 °C under 5 % CO2 atmosphere using
Endothelial Cell Basal MV2 Medium (C-22221, Promo-
Cell, Germany) supplemented with MV2 supplement
pack (C-39221, PromoCell, Germany). For experiments,
hCMEC/D3 cells were between passage 25 and 35.
Human NSCLC cell lines, A549 and SK-MES-1, were
purchased from the European Collection of Cell Cultures
(ECACC; Salisbury, UK) and cultured in Dulbecco’s Modi-
fied Eagle Medium (DMEM, Lonza, Slough, UK) supple-
mented with L-glutamine (2 mM), gentamicin (50 μg/ml)
and 10 % (v/v) FBS (Sigma Aldrich, Gillingham, UK).
For collection of lung tumour conditioned-medium
(CM), A549 and SK-MES-1 cells at 80 % to 90 % conflu-
ence were washed with PBS (x3) and incubated with chem-
ically defined DMEM-BS medium [13] (1 ml of medium
per 7.5 cm2 of growth area) for 24 h at 37 °C. Media were
then centrifuged (600 g, 10 min, 4 °C) and stored at −80 °C
for further experiments.
Mass spectrometry analysis and ELISA
ELISA and LC-MALDI TOF/TOF mass spectrometry
(MS) were carried out to screen the secretome (as CM) of
A549 and SK-MES-1 cells (see Additional file 1 for experi-
mental details). Analyses were also carried out on DMEM-
BS as a control. DMEM-BS is a serum-free chemically
defined medium specially formulated by Bottenstein &
Sato from DMEM [13]. Since the formulation is known,
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any additional factors secreted into CM could be easily
identified. Significant results were determined by selecting
proteins that matched with two or more peptides with total
ion CIs of >95 %, followed by a literature search to deter-
mine proteins with a possible role in metastasis. The fol-
lowing tumour secreted metastasis-related proteins were
identified from the available literature: tumour necrosis
factor-alpha (TNF-α) [14], cathepsin L (CL) [15], cystatin
C (CC) [16], vascular endothelial growth factor (VEGF)
[17] and insulin-like growth factor binding protein-7
(IGFBP-7) [18].
Secreted levels of TNF-α, CL, CC, VEGF-A and
IGFBP-7 in the A549 and SK-MES-1 CM were measured
by ELISA (TNF-α and CC: Bender MedSystems, Vienna,
Austria; CL: R&D systems, Abingdon, UK; VEGF-A: Pepro-
Tech®, London, UK) and IGFBP-7: in house ELISA previ-
ously described in [18].
Treatment conditions
During the various investigations, with the exception of
E-selectin ELISA, hCMEC/D3 cells were incubated with
either complete lung tumour CM (A549 CM and SK-
MES-1 CM) or individual tumour secreted-proteins (at
concentrations detected during the previous ELISAs) –
80 ng/ml CC (Abcam, Cambridge, UK), 10 ng/ml CL
(Sigma Aldrich, Gillingham, UK), 200 ng/ml IGFBP-7
(Abcam, Cambridge, UK), 0.2 ng/ml VEGF-A (R&D Sys-
tems, Abingdon, UK) and 160 pg/ml TNF-α (Enzo Life
sciences, Exeter, UK). All of the aforementioned solu-
tions were prepared in DMEM-BS, and control cells
received DMEM-BS only.
Cell surface based ELISA (E- and P-selectin)
Surface levels of E- and P-selectin on human cerebral endo-
thelial cells (ECs) were assessed using a semi-quantitative
cell based ELISA as previously described in [19]. Cells were
cultured in collagen I coated 96-well plates; once a mono-
layer had formed they were serum starved overnight and
treated with increasing concentrations of identified tumour
secreted-proteins (in DMEM-BS) for 4 h; CC – 8, 80 and
800 ng/ml, CL – 1, 10 and 100 ng/ml, IGFBP-7 – 100, 300
and 900 ng/ml, VEGF-A – 0.2, 10 and 20 ng/ml and TNF-
α – 100, 500 and 2500 pg/ml and/or lung tumour CM.
Exposed selectin molecule was recognised by an anti-E- or
P-selectin antibody and all subsequent ELISA incubation
and washing steps are described in Additional file 1.
Laminar flow adhesion assay
The adhesion of lung cancer cells to the brain endothe-
lium was assessed using an in vitro flow model, where
treated hCMEC/D3 monolayers in gas-permeable flow
chambers were perfused with a suspension of lung
tumour cells. ECs were cultured and treated as required
in collagen I coated flow chambers (ibidi μ-slides I and
VI0.4, Thistle Scientific, Glasgow UK). After 4 and 24 h,
A549 or SK-MES-1 cells (1 x 106 cells/mL) stained with
0.5 μM calcein acetoxymethyl ester (Calcein AM; Life
Technologies Ltd, Paisley UK) were flowed over the
monolayers at a flow rate calculated to provide a shear
stress of 1dyne/cm2, i.e. low shear stress comparable to
that found in post-capillary venules where the majority
of adhesion occurs, for 10 min at 37 °C [20]. To remove
any non-adherent tumour cells, the slides were rinsed
with PBS for 2.5 min at 37 °C before being fixed with
4 % paraformaldehyde. The flow slides were then exam-
ined under a Nikon Eclipse TS100 fluorescence micro-
scope and the number of adherent A549 or SK-MES-1
cells in 10 random fields of view were counted, concen-
trating on central areas rather than borders.
For the E-selectin inhibition experiments, endothelial
monolayers were treated for 24 h with CM and
secreted-proteins and then exposed to monoclonal anti-
E-selectin antibody (5 μg/ml, clone 1.2B6, Sigma Al-
drich, Gillingham, UK) for 30 min prior to perfusion
with calcein AM stained A549 and SK-MES-1 cell sus-
pensions (as described above). The optimum conditions
for anti-E-selectin treatment were determined previously
through time- and concentration-dependent inhibitory
experiments.
Flow cytometry analysis of adhesion molecule counter
ligands/receptors
Expression of adhesion molecule counter ligands and
receptors on A549 and SK-MES-1 lung tumour cells were
investigated by flow cytometry (FC); specifically the E-
selectin ligand sialyl Lewis X (sLeX), ICAM-1 receptors,
lymphocyte function-associated antigen 1 (LFA-1α/CD11a)
and macrophage-1 (Mac-1α/CD11b) and VCAM-1 recep-
tor, very late antigen-4 (VLA-4α/CD49d). See Additional
file 1 for experimental details.
Cell based fluorescence assay
A cell-based fluorescence (CBF) assay, as previously de-
scribed by Singh and colleagues [21], was performed to
quantify changes within the glycocalyx using fluores-
cein isothiocyanate-labelled wheat germ agglutinin
(WGA-FITC), which binds to N-acetyl neuraminic acid
and N-acetyl glucosamine residues of proteoglycans
and glycoproteins present in the glycocalyx.
Lectin-binding (as WGA-FITC binding) was also ob-
served (as previously described [22]), before and after
1 h treatment with lung tumour CM, with a confocal
laser scanning microscope (Leica DMi8 TCS SP8 Con-
focal, Leica Microsystems, Germany). The images (1024
x 1024 pixels) were acquired with a 10x tube lens and
processed using the Leica LAS X Core software.
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Glycocalyx constituents ELISA – Hyaluronic acid and
Syndecan-1
Hyaluronic acid (HA) and syndecan-1 (CD138) levels in
CM-treated endothelial supernates were measured using
the R&D Systems (Abingdon, UK) Quantikine Hyaluronan
Immunoassay kit (DHYAL0) and the Syndecan-1 Human
ELISA kit (ab46506) by Abcam (Cambridge, UK). See
Additional file 1 for experimental details.
Statistical analysis
Data are presented as mean ± standard deviation (SD) and
statistical differences between control and treatment groups
were assessed using Mann–Whitney non-parametric test.
P-value ≤ 0.05 is considered statistically significant.
Results
Lung cancer cells secrete a range of factors with a
potential role in mediating brain metastasis
Initially, MS was used to screen the secretome (as CM) of
A549 and SK-MES-1 cells for the presence of metastasis-
related proteins. As expected both cell types secreted a
large range of proteins not present in the DMEM-BS con-
trol (see tables S1, S2 and S3 in Additional file 2). However,
only the following three proteins were identified to have a
possible role in metastasis and investigated further: CC, CL,
and IGFBP-7. Surprisingly, no growth factors or cytokines
were detected using this approach, presumably due to limi-
tations of MS in identifying proteins in complex mixtures,
such as CM, and instrument limitation. Thus, ELISAs were
carried out to quantify the secreted levels of the proteins
identified above and to investigate whether the tumour cells
secreted other known pro-angiogenic factors including
VEGF-A and TNF-α. Figure 1 shows the concentrations of
VEGF-A, TNF-α, CC, CL, and IGFBP-7 in CM from both
cancer cell lines. The concentrations of measured proteins
did not vary greatly between A549 and SK-MES-1 CM.
Lung tumour secreted-proteins induce increased exposure
of selectins on the surface of human cerebral ECs
Metastasis critically requires adhesion of the circulating
tumour cells (CTCs) to the endothelium of secondary
organs, possibly utilising endothelial selectins. Thus, the
influence of the lung tumour secreted proteins (at a con-
centration range based on protein levels measured in
CM) on cerebral EC E- and P-selectin surface levels was
investigated. Enhanced E-selectin surface expression typ-
ically requires de novo synthesis usually triggered by an
inflammatory stimulus and peaks approximately 4–6 h
after activation. After 4 h, all tumour secreted-proteins
induced a significant increase in surface E-selectin at ei-
ther higher concentrations tested (CC, IGFBP-7) or over
the whole concentration range (CL, VEGF-A, TNF-α)
(Fig. 2). Based on the obtained data and the protein con-
centrations measured in CM, subsequent studies used
only one concentration of each protein: CC 80 ng/ml; CL
10 ng/ml; IGFBP-7 200 ng/ml; VEGF-A 0.2 ng/ml and
TNF-α 160 pg/ml. At these concentrations the proteins sig-
nificantly increased detected endothelial E-selectin levels to
226 ± 73.1 %, 285 ± 129.2 %, 210 ± 70.9 %, 229 ± 45.1 % and
189 ± 59.1 % compared to control (100 %) (p ≤ 0.01).
Cerebral ECs exposed to both A549 and SK-MES-1 CM
also demonstrated enhanced levels of surface E-selectin at
4 h (272 ± 96.1 % and 177 ± 70.4 % respectively). Interest-
ingly, a significant increase was detected even after 30 min
treatment (Fig. 2a) (132 ± 4.6 % and 125 ± 7.2 %) (p ≤ 0.05).
This was also evident with the tumour-secreted proteins
at their chosen concentrations (CC: 146 ± 42.3 %, CL: 153
± 33.4 %, IGFBP-7: 143 ± 28.5 %, VEGF-A: 146 ± 41.0 %
and TNF-α: 122 ± 11.2 %) (Fig. 2b).
Furthermore, at 30 min A549 CM also appeared to
significantly enhance the exposure of P-selectin on the
surface of hCMEC/D3 cells (128 ± 30.6 % v control 100 %)
(p ≤ 0.037, n = 3). There was no increase in P-selectin
levels detected with SK-MES-1 CM.
Lung tumour secreted-proteins enhance adhesion of lung
tumour cells to human cerebral microvascular endothelial
cells
The observation that A549 and SK-MES-1 lung tumour
cells secrete factors that enhance surface levels of E-
selectin led us to investigate whether this was reflected in
altered adhesion of lung tumour cells (over 10 min) to
similarly treated endothelial monolayers. Using a flow
adhesion assay to mimic microvascular flow conditions, it
was observed that adhesion of both lung tumour cell types
to cerebral EC monolayers was significantly increased by
previous exposure to relevant whole CM. With 24 h treat-
ment, adhesion was enhanced to 358 ± 20.5 % (A549) and
476 ± 45.1 % (SK-MES-1 CM) compared to control levels
(100 %) (p ≤ 0.05, Fig. 3a & c) Interestingly, a reduced, but
still significant, increase in tumour cell adhesion was also
observed after only 30 min of A549 and SK-MES-1 CM
treatment; 137 ± 17.3 % and 170 ± 85.4 %, respectively.
Treatment of cerebral ECs with all of the identified tumour
secreted-proteins significantly increased adhesion of both
Fig. 1 Potential prometastatic proteins were identified and quantified
in human NSCLC cell secretome. ELISA analysis of CC, CL, IGFBP-7, TNF-α
and VEGFA concentration in A549 and SK-MES-1 CM. All experiments
were carried out in duplicate on three separate samples
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lung tumour cell types to the monolayer. 24 h treatment
with CC, CL, IGFBP-7, VEGF-A and TNF-α enhanced
A549 cell attachment to 568 ± 40.5 %, 535 ± 22 %, 424 ±
36.1 %, 386 ± 18.6 % and 356 ± 18.8 %, respectively. Again,
a reduced but still significant effect was observed at the
shorter treatment time studied. Overall, SK-MES-1 cell
Fig. 2 Increased levels of E-selectin detected on the surface of human cerebral microvascular endothelial cells in response to lung tumour CM and
secreted-proteins. Confluent hCMEC/D3 cells were stimulated for 4 h with A549 and SK-MES-1 CM (a) along with CC (c), CL (d), IGFBP-7 (e), VEGF (f)
and TNF-α (g). E-selectin levels from 3 separate experiments, carried out in quadruplets, were statistically analysed (n≥ 12, mean ± SD, *p≤ 0.05 and
**p ≤ 0.01, ***p ≤ 0.005 and ****p ≤ 0.0001). Enhanced E-selectin was also detected within 30 min of CM (a) and secreted-proteins (b) exposure
(*p ≤ 0.05 and **p ≤ 0.01, n = 6)
Rai et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:105 Page 5 of 12
adhesion was more pronounced in response to the
secreted-proteins; at 24 h this rise was approximately 8-fold
with IGFBP-7 and VEGF-A (788 ± 302.3 % and 817 ±
167.6 %). CC, CL and TNF-α also increased adhesion to
462 ± 4.6 %, 501 ± 10.7 % and 530 ± 15.6 %, respectively.
Inhibiting E-selectin binding fully attenuated lung cancer
cell adhesion to cerebral ECs
These data suggest that lung cancer secreted-factors influ-
ence tumour cell adhesion to cerebral endothelial mono-
layers by inducing enhanced surface levels of E-selectin. To
verify the role of E-selectin, blocking studies using a mono-
clonal antibody against E-selectin were performed. Treat-
ment of the endothelial monolayer with anti-E-selectin
antibody fully attenuated the increased adhesion of A549
and SK-MES-1 lung cancer cells (Fig. 4) induced by the
tumour secreted-proteins. Isotype-matched control (mouse
monoclonal IgG1) studies confirmed the specificity of the
inhibition to the anti-e-selectin antibody (see Additional
file 3: Figure S1).
Since these data strongly indicate a role for E-selectin
in the adhesion of lung tumour cells to the cerebral
Fig. 3 Lung tumour CM and secreted-proteins enhance adhesion of A549 and SK-MES-1 cells to human brain endothelial monolayers. Confluent
hCMEC/D3 cells in μ-slides were exposed to A549 CM or SK-MES-1 CM for 30 min and 24 h prior to perfusion with calcein AM stained A549 (a)
or SK-MES-1 cells (c). A549 and SK-MES-1 adhesion to hCMEC/D3 cells treated with 80 ng/ml CC, 10 ng/ml CL, 200 ng/ml IGFBP-7, 0.2 ng/ml VEGF
and 160 pg/ml TNF-α at 4 and 24 h (b) and (d). Mean values from three separate experiments were statistically analysed. * p≤ 0.05 versus control
levels (100 %). e Representative images of adherent calcein-AM stained A549 [(i) and (ii)] and SK-MES-1 [(iii) and (iv)] cells to DMEM-BS [(i) and (iii)]
and CL-treated [(ii) and (iv)] brain endothelial monolayers. Scale bar = 75 μm
Rai et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:105 Page 6 of 12
endothelium, the expression of counter adhesion ligands
and receptors on the tumour cells was investigated i.e.
the E-selectin ligands sialyl Lewis X (sLeX) and P-selec-
tin glycoprotein ligand-1 (PSGL-1), ICAM-1 receptors,
lymphocyte function-associated antigen 1 (LFA-1α/
CD11a) and macrophage-1 (Mac-1α/CD11b) and VCAM-
1 receptor, very late antigen-4 (VLA-4α/CD49d). Both
A549 and SK-MES-1 cells displayed relatively high levels
of sialyl Lewis X compared with the other antigens
investigated (Fig. 4c). Indeed, levels of VLA-4α, LFA-
1α, PSGL-1 and Mac-1α were all very low (<5 %) on
both cell types. Isotype-matched (IgM, κ) and positive
controls corroborated these findings. The expression
of VLA-4α, LFA-1α and Mac-1α was clearly evident
Fig. 4 E-selectin inhibition attenuated adhesion of A549 and SKMES-1 lung cancer cells to human cerebral microvascular endothelial cells.
Confluent hCMEC/D3 cells were treated with A549 CM (a), SK-MES-1 CM (b) and secreted-proteins for 24 h prior to exposing the relevant channels
with anti-E-selectin antibody for 30mins. The bars represent cancer cell adhesion to brain endothelial monolayer calculated as a percentage of control
obtained on 3 separate occasions. (* p ≤ 0.05 vs control, #p ≤ 0.05, ##p ≤ 0.01 vs anti-E-selectin). c FC analysis of adhesion molecule ligands and
receptors, CD49d, CD11a, CD11b, PSGL-1 and sLeX, on lung tumour cells. The presented data was collected from 3 different experiments
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(>30 %) on U937 cells and freshly isolated human
monocytes, included as a positive control (see Additional
file 4: Figure S2).
The cerebral endothelial glycocalyx is significantly altered
by lung tumour CM and secreted-proteins
E-selectin is transcriptionally regulated and increased sur-
face expression is reported to take a minimum of 2 h. Thus,
the observation that lung tumour secreted-factors signifi-
cantly enhance both exposure of cerebral endothelium
surface E-selectin and tumour /endothelial cell interac-
tions within 30 min suggests that an additional, alternative
mechanism contributes to regulation of tumour/endothe-
lial interactions. The endothelial glycocalyx may influence
cell adhesion interactions through steric effects on adhesion
molecule/ligand binding dynamics. We therefore hypothe-
sised that the lung tumour secretome could alter the integ-
rity of the cerebral endothelial glycocalyx, leading to the
increased exposure of previously ‘hidden’ E-selectin mole-
cules and facilitating enhanced lung tumour cell adhesion.
A cell-based fluorescence assay was used to quantify
changes within the glycocalyx. Significant reduction in
glycocalyx staining of cerebral ECs occurred rapidly i.e.
within 30 min of lung tumour CM treatment (A549 CM:
84 ± 1.7 % and SK-MES-1 CM: 76 ± 7.1 %, vs. control, 100
%, Fig. 5a, d, e), suggesting loss of glycocalyx integrity. An
even greater reduction in glycocalyx staining was observed
after 24 h to 45 ± 10.9 % and 42 ± 17.1 % after exposure to
A549 and SK-MES-1 CM, respectively vs control (100 %).
Interestingly, the effect of CM was more pronounced than
that of the F. heparinum heparinase III enzyme (positive
control, 71 ± 15.9 %), which exclusively cleaves heparan
sulphate glycosaminoglycans within the glycocalyx (Fig. 5a).
Treatment of the endothelial monolayer with CC, CL,
IGFBP-7, VEGF-A and TNF-α also significantly altered the
cerebral endothelial glycocalyx at both time points, with the
Fig. 5 Exposure of lung tumour CM and secreted-proteins significantly altered the brain endothelial glycocalyx. a and b Integrity of the
hCMEC/D3 glycocalyx was assessed by a CBF assay following exposure of ECs for 30 min or 24 h to A549 and SKMES-1 CM (a), or 80 ng/ml
CC, 10 ng/ml CL, 200 ng/ml IGFBP-7, 0.2 ng/ml VEGF and 160 pg/ml TNF-α (b). Data from 6 independent experiments, carried out in sextuplicate, is
presented as WGA-FITC fluorescence/μg protein and these values were calculated as a percentage of control. *p≤ 0.05, **p≤ 0.01 vs control level. c
Hyaluronan (HA) and syndecan-1 levels were measured by ELISA in hCMEC/D3 growth medium following 30 min treatment with fresh DMEM-BS (control),
A549 or SK-MES-1 CM. SK-MES-1 CM vs control = p= 0.007, n= 6. nd = not detected. d and c Representative confocal images of FITC-WGA stained hCMEC/
D3 cells before (d) and (e) after 30 min exposure to SKMES-1 CM. Scale bar = 40 μM
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greatest reduction in staining observed with 24 h VEGF-A
and TNF-α treatment, respectively (52 ± 26.5 % and 57 ±
28.3 % vs control 100 %, Fig. 5b).
Disruption or shedding of the glycocalyx can also be
assessed by measuring the release/loss of key components
such as syndecan, heparan sulphate and hyaluronan.
Syndecan-1 is a proteoglycan core protein while hyaluro-
nan or hyaluronic acid (HA) is one of the glycosaminogly-
cans (GAG) and both contribute to the stability of the
glycocalyx structure [23]. HA or syndecan-1 release into
the supernatant during lung tumour CM exposure was
used as an additional measure of glycocalyx degradation;
determined respectively by hyaluronan and syndecan-1
ELISA. After 30 min, significantly increased levels of HA
were detected in the SK-MES-1 CM treated endothelial
supernate (56.94 ± 23.6 ng/ml vs control, 0.74 ± 0.04 ng/
ml) and raised syndecan-1 levels (1.15 ± 1.09 ng/ml vs
control [not detected]) were observed in the A549 CM
exposed endothelial supernates (Fig. 5c).
Discussion
Although, the exact mechanisms involved in the arrest and
extravasation of CTCs during metastasis are still not fully
understood, adhesion to, and transmigration through, the
vascular endothelium is critically required. In the brain, the
endothelium is an integral component of the blood–brain
barrier (BBB), which due to its highly impermeable nature,
presents a formidable challenge to the passage of metasta-
sising CTCs.
An increasing number of reports highlight a role for
endothelial adhesion molecules in the tethering of CTCs to
the endothelium. This process may be additionally regu-
lated by the steric effects of the endothelial glycocalyx
which, in health, shields the adhesion molecules from circu-
lating cells. Glycocalyx loss in response to metastasising
tumour cells could favour attachment of tumour cells to
the vessel wall, facilitating metastatic progression [24]. We
hypothesised that both adenocarcinoma and squamous
human lung tumour cells metastasising to the brain actually
secrete factors that facilitate their own adhesion to the cere-
bral endothelium, thus enhancing their metastatic potential.
Our data indicate, for the first time, that adenocarcinoma
and squamous human lung tumour cells secrete proteins
that not only disturb the integrity of the human cerebral
endothelial glycocalyx, but concomitantly increase endothe-
lial surface exposure of E-selectin and the binding of flow-
ing tumour cells to the cerebral endothelium. Additionally,
human lung adenocarcinoma tumour cells secrete proteins
that enhance P-selectin exposure. These data suggest a crit-
ical role for the glycocalyx and cerebral endothelial adhe-
sion molecules in the initial stages of extravasation during
lung tumour metastasis to the brain.
Initial proteomic analysis of the secretome of two
NSCLC subtypes, A549 (adenocarcinoma) and SK-MES-1
(squamous cell carcinoma), detected several secreted pro-
teins with a potential role in tumour development or
metastasis i.e. CC, CL, IGFBP-7, VEGF-A and TNF-α. It is
interesting to note that the measured secreted levels of
VEGF were relatively low compared to some of the other
proteins detected. However, comparable, picogram levels
of VEGF-A have been reported in the plasma of cancer
patients [25] and to have significant effects on endothelial
function [26]. The pathogenic role of VEGF in tumour
growth is well documented (reviewed in [17]) and not only
has enhanced VEGF expression been observed in all forms
of NSCLC, but also high serum levels have been corre-
lated with poor prognosis in patients [27, 28]. TNF-α,
however, has been reported to have both pro- and anti-
tumour effects [29]. For instance, in NSCLC a positive
correlation has been identified between high TNF-α
expression and favourable prognosis [30]. In contrast, not
only have pro-tumourigenic effects of TNF-α been
reported in various cancers e.g. breast [14], but interest-
ingly, anti-TNF-α treatment of inflammatory diseases has
led to a significant rise in the rates of malignancies in
patients [31]. CC is a potent inhibitor of cysteine prote-
ases. It also has contradictory roles in cancer pathogenesis;
while expression of CC has been shown to be down-
regulated in various aggressive metastatic tumours includ-
ing prostate [32], increased plasma levels have been
reported in patients suffering from a range of malignancies
including lung cancer [16]. CL is an endopeptidase that de-
grades a range of proteins including collagen I and IV and
elastin. It has been reported to promote cancer invasive-
ness by catalysing breakdown of the interstitial matrix and
basement membrane [15]. IGFBP-7 is a member of the
IGFBP superfamily [33] and binds to insulin-like growth
factors (IGFs) with high affinity; regulating their activity by
preventing ligand/receptor interactions. We and others
have demonstrated a pro-angiogenic role for IGFBP-7. Ex-
ogenous IGFBP-7 induced proliferation, migration and tu-
bule formation in omental microvascular endothelial cells
[18] and induced tube-like structure formation in brain
ECs [34]. Additionally, IGFBP-7 is implicated in the biol-
ogy of a range of tumours including lung squamous cell
carcinoma [35] and head and neck squamous cell carcin-
oma [36]. All five of these identified secreted-proteins and
complete tumour CM significantly enhanced exposure of
E-selectin on human cerebral microvascular endothelial
monolayers and importantly, these changes were reflected
in increased binding of the relevant lung tumour cells to
the endothelial monolayer during 10 min perfusion.
The role of E-selectin in the lung tumour/endothelial
adhesion was confirmed by blocking experiments using an
anti-E-selectin antibody which completely attenuated the
enhanced tumour/endothelial cell binding induced by the
lung tumour secreted-factors. Additionally, flow cytometry
analysis confirmed the expression of the E-selectin ligand
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sLeX on the surface of both lung tumour cell types. The
observation that sLeX expression was higher in the A549
cell population than in SK-MES-1 cells is consistent with
other studies that have demonstrated greater expression
of sLeX antigens in lung adenocarcinomas than in squa-
mous cell carcinomas [37]. The enzymes responsible for
synthesizing sLeX such as α (1, 3) - fucosyltransferases are
up-regulated in lung carcinomas, which could contribute
to the adhesive and metastatic potential of lung cancer
cells [38].
The observed role for E-selectin in lung tumour metasta-
sis to the brain is in agreement with studies implicating E-
selectin in metastasis in other cancer models. For instance,
recent studies in a mouse model have demonstrated endo-
thelial and tumour cell expression of E-selectin in brain
metastases induced by metastatic murine mammary carcin-
oma cells [8]. The rapid (i.e. within 30 min) enhancement
of lung tumour adhesion and surface exposure of E-selectin
in both lung tumour cell types suggested that the tumour
cells triggered additional adhesive mechanisms other than
simply stimulating a transcriptionally regulated increase in
surface expression of E-selectin. This raised the possibility
that the interaction between the lung cancer cells and the
endothelium is additionally regulated by the endothelial gly-
cocalyx. Since, in health the length of glycocalyx compo-
nents often exceeds that of the endothelial adhesion
molecules, we investigated whether factors secreted from
lung tumour cells could induce the rapid loss of cerebral
endothelial glycocalyx; exposing the previously shielded
adhesion molecules and facilitating adhesion. We show for
the first time that factors secreted from both lung cancer
subtypes rapidly and significantly induced degradation of
the cerebral glycocalyx layer as assessed by WGA-FITC
binding and shedding of glycocalyx components. Our previ-
ous data has confirmed that this lectin almost exclusively
stains the luminal glycocalyx in cultured ECs [22]. The
mechanism of glycocalyx modification or degradation in
response to all of the tumour secreted-proteins can only be
speculated at this point. These data are the first to show
that CL, CC and IGFBP-7 induce glycocalyx changes and
for the latter two proteins there is no available literature de-
scribing a role in glycocalyx degradation. CL may mediate
glycocalyx damage indirectly by activating other glycocalyx
degrading enzymes, e.g. heparanase, since formation of the
active form of this enzyme from its precursor is exclusively
catalysed by CL. However, since CL induced such rapid
glycocalyx changes in cerebral endothelial cells an as yet
unidentified, direct role on glycocalyx components cannot
be ruled out.
TNF-α and VEGF have both been reported to alter the
glycocalyx in other endothelial cell types. Henry and
Duling suggested that TNF-α could directly stimulate
the endothelium to either shed glycocalyx components,
release free radicals, or activate surface-bound proteases or
phospholipases that degrade it, such as endothelial-derived
metalloproteases [39]. VEGF is able to directly regulate
synthesis and shedding of glycocalyx components e.g. in
glomerular endothelial cells [40] and has also been reported
to induce changes in vessel permeability by causing struc-
tural glycocalyx alterations [41].
It is interesting to note that while significant and func-
tionally relevant glycocalyx changes were observed within
30 min, the effects of longer treatment of cerebral endo-
thelial cells with lung tumour secreted-factors induced
even greater levels of E-selectin exposure and tumour cell
adhesion. It is thus possible that the effects of lung tumour
secreted factors is two-fold – not only inducing rapid
glycocalyx perturbations which facilitate functional re-
sponses i.e. increased adhesion, over the shorter term, but
inducing enhanced longer term responses resulting from
even greater glycocalyx loss augmented by induction of
increased cellular E-selectin protein expression and trans-
location to the cell surface.
Conclusions
In summary, our data indicate a critical role for the cerebral
EC glycocalyx and E-selectin/sLeX axis in regulating the
adhesion of circulating lung tumour cells to the brain mi-
crovasculature; a key process in metastatic colonisation.
We propose a cascade initiated by the secretion of pro-
metastatic proteins from the lung tumour cells, which alter
the cerebral endothelial glycocalyx structure revealing the
E-selectin molecules on the endothelial cell surface. The E-
selectin is then available to bind to sLeX ligand on the
tumour cells facilitating the stronger bonds required for
tethering and capture, ultimately enabling extravasation
and secondary growth in the brain. Our data suggest that
combining inhibitors capable of interrupting the contacts
between E-selectin and its ligand along with preservation of
glycocalyx integrity may represent a novel treatment mo-
dality for reducing brain metastasis in primary lung tumour
patients.
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